Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

United Therapeutics Corp

NASDAQ: UTHR · Life Sciences · 48 alerts · CIK 1082554

Share price
$587.88Close, Nov 16
Market cap
$25B
Shares outstanding
42.59MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All United Therapeutics Corp filings on SEC EDGAR ↗

6:32 AM ET 8-K
Financial Results

United Therapeutics Financial Results

United Therapeutics reported third quarter 2026 total revenues of $832.5 million, a 4% increase year-over-year, driven primarily by growth in Tyvaso DPI and Orenitram sales. Net income for the quarter was $258.6 million, or $5.71 per diluted share, representing a 24% decrease compared to the prior year period.

Term
Q3 2026

“United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve.”

Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics

“Our record third quarter revenue performance reflects a business operating at a very high level, driven by strong commercial momentum and focused execution across our organization.”

Michael Benkowitz, President and Chief Operating Officer of United Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.